Protalix Signs $8.3M Deal With Pfizer

Israeli pharmaceutical company Protalix has signed a development deal with pharmaceutical giant Pfizer, for the continuation of development of its Elelyso drug. According to the agreement, Portalix will continue to conduct the clinical trials for the drug, which is currently being tested on children and adults. As part of the agreement, the Israeli company will receive up to $8.3 million for milestone achievements.